FRESENIUS SE, Divestment of the loss-making Biotech division and completion of Fenwal acquisition

News published on December Friday 14, 2012
Share on
As expected, Fresenius SE has decided to focus on its 4 key franchises: Kabi, Medical Care, Helios and Vamed. Therefore the company will shut its Biotech division which was making losses despite having two products on the market (9M 2012: EUR26m of sales, +15%). In FY 2012, operational losses will reach around EUR25m and have a negative impact on group EBIT margin of 20 bps.

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities